[Antibody-based agents as experimental therapeutic interventions for corneal allograft rejection]

The corneal allograft rejection is the primary reason for graft failure, but the existing agents are of limited efficacy and may be accompanied by unacceptable morbidity. Recently, antibody-based agents have received great attention and have become an important part of therapeutic intervention for organ transplantation, which is also a research focus in the field of corneal transplantation. This review summarizes the history, current situation and mechanism of antibody-based agents in corneal transplantation.